

## REMARKS

In compliance with 37 C.F.R. § 1.821 through § 1.825, applicants have amended the specification to add Sequence Identifiers. No new matter has been added by this amendment. Applicants respectfully request entry of the present amendment.

## CONCLUSION


Attached hereto is a marked up version of the changes made to the specification by the current amendment with additions underlined and deletions bracketed. The attached pages are captioned "**VERSION WITH MARKINGS TO SHOW CHANGES MADE**".

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **220002057125**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: February 25, 2002

By:

  
Catherine M. Polizzi  
Registration No. 40,130

Morrison & Foerster LLP  
755 Page Mill Road  
Palo Alto, California 94304-1018  
Telephone: (650) 813-5651  
Facsimile: (650) 494-0792

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

On page 91, please replace the paragraph which begins on line 29 with the following:

Replacement of residues Arg 118-Lys119-Tyr120-Thr121-Ser122 of FGF-2 (SEQ ID NO: 15) with the human sequence Ala-Gln-Phe-Pro-Asn (SEQ ID NO: 16) from the corresponding loop of the structural analogue IL-1 $\beta$  (115-119) was essentially performed as follows:.

**In the Claims:**

46. (Amended) A method according to [one of] claim[s] 1 [to 45], wherein the step of introducing a vector into at least one coronary artery is performed coincident with or following infusion of the artery with a vasoactive agent.

62. (Amended) The method of claim 62 58, wherein the conduit delivering blood to the tissue blood vessel is selected from the group consisting of a coronary artery and a femoral artery.

55. (Amended) A method according to [one of] claim[s] 1 [to 45 or 52 to 54], wherein said patient is a human.

110. (Amended) A method according to [one of] claim[s] [52 to 54 or] 57 [to 109], wherein the step of introducing a vector into at least one coronary artery is performed coincident with or following infusion of the artery with a vasoactive agent.

119. (Amended) A method according to [one of] claim[s] 57 [to 109 or 116 to 118], wherein said patient is a human.

152. (Amended) A kit comprising a gene therapy composition according to [one of ]claim[s] 121 [to 151].